135例急性感染性疾病所致肝功能损害临床分析

目的　分析临床急性感染性疾病所致肝功能损害的特点及其恢复时间。方法　对 135例急性感染性疾病患者入院肝功能指标进行分析 ,观察治疗第 2周及第 4周时患者异常肝功能指标恢复情况。结果　除 6例死亡外 ,其余患者异常肝功能指标升高多在正常值上限 3倍以内 ,治疗第 4周异常肝功能指标治愈率分别为 AL T92 .4%、AST91.6 %、GGT75 .6 %、AL P91.3%、 SB10 0 %、 SB’ 10 0 %和 TBA 85 .7% ,HBs Ag ( )携带者与 HBs Ag (- )者治疗第 4周上述指标治愈率无显著差异。第 4周时 GGT仍升高者恢复缓慢或不易恢复正常。结论　急性感染性疾病致肝功能损害多呈轻度及一过性升高 ;HBs Ag ( )携带者肝脏应急储备及修复功能较正常人无明显下降 ;GGT恢复缓慢或不易恢复正常者可能留有持久性的肝内毛细胆管损伤     

茜草多糖对肾缺血再灌注损伤的保护作用

目的 :观察茜草多糖对肾缺血再灌注损伤的保护作用。方法 :通过建立大鼠急性肾缺血再灌注损伤模型 ,测定了茜草多糖对肾缺血再灌注后 ,MDA、SOD以及肾组织中Na ,K ATP酶及Ca2 ATP酶活性的变化。结果 :使用茜草多糖后 ,与对照组比较MDA明显降低。SOD、Na 、K ATP酶及Ca2 ATP酶的活性显著上升。结论 :茜草多糖对急性肾缺血再灌注损伤肾脏有显著的保护作用。     

普米克气雾吸入对咳嗽变异型哮喘患者气道高反应性及肺功能的影响

采用普米克气雾吸入治疗 48例咳嗽变异型哮喘患者。结果表明 :治疗组气道高反应性显著降低 (P <0 .0 0 1) ,肺功能显著改善 ( P <0 .0 0 1) ,与对照组比较差异有显著性 ( P <0 .0 1)。证实普米克吸入对改善咳嗽变异型哮喘病人肺功能及降低气道高反应性疗效肯定 ,有积极意义     

重组人白细胞介素-1β对人红系、粒系造血祖细胞集落形成的影响

为探讨重组人白细胞介素-1β(rhIL-1β)对人红系、粒系造血祖细胞的作用,采用96孔板微量培养法在体外进行培养。在培养中加入不同浓度的rhIL-β1(0～5ug/mL)后,观察BFU-E、CFU-E及CFU-GM的集落形成。结果加入不同浓度的IL-1β后,BFU-E、CFU-E的集落形成均受到抑制,且呈剂量依赖性,在IL-1β剂量为0.1和0.5μg/mL时,抑制作用更明显(JP<0.005,0.05),而IL-1β对CFU-GM的集落形成无明显影响。结果表明,IL-1β对红系造血祖细胞(BFU-E和CFU-E)影响的研究有助于解释某些慢性疾病性贫血(如类风湿性关节炎伴贫血等)的发生机制,提示IL-1β单克隆抗体有可能用于治疗慢性疾病性贫血。     

Retrospective Study on the Efficacy and Safety of Quinacrine Sterilization

Objective To observe and evaluate the efficacy and safety of quinacrine sterilization.Methods A total of 572 cases of quinacrine sterilization preformed during the 4 years from 1993to 1997in Jiangsu and Guizhou Provinces were employed in this study. The efficacy and safety of quinacrine sterilization in those case were studied and evaluated, with 588 cases of surgical sterilization performed at the same time being the control group.Results Both groups were with identical demographic and gynecological characteristics. The result of multiple decrement life table analysis showed the 12th gross cumulative failure rates for quinacrine sterilization was 3. 13% and serious side effects occurred in only 2 cases accounting for O. 35%. One was ectopic pregnancy (20 months after treatment). The other was due to anaphylaxis in 10 minutes after the second insertion). No difference in the liver and nephic functions was detected and no suspected cancer cells or cancer cells were found in the two groups. 99. 6% of the 572 women interviewed accepted the quinacrine sterilization.Conclusions Quinacrine sterilization method is with high acceptability but comparatively low effectiveness. It has been proved to be a safe method of contraception in short-term. However, the safety of long-term still needs further study.     

严重烧伤病人早期肾功能损害与早期糖尿症的相关性研究

目的 :通过对严重烧伤病人进行应激性糖尿症和早期肾功能损害等并发症观察研究 ,进一步了解其发病机制。方法 :对重度烧伤病人进行血 BS、BUN、Cr、UA、TNFα、INS、β2 - MG及尿糖、尿 PRO、尿 p H、尿β2 - MG等进行监测。结果 :发现 5例病人在血糖不高的情况下出现糖尿和不同程度的肾功能损害。结论 :部分严重烧伤病人早期糖尿是由肾脏近曲小管吸收障碍引起。     

持续顺行灌注温血停搏液对心肌的保护作用

研究持续灌注温血停搏液对心肌的保护作用,探讨理想的心肌保护策略,方法６９只猫随机分为对照组、损伤组和保护组。观察测各组不同时间点心功能、心肌细胞膜ＡＴＰａｓｅ活性心肌细胞膜蛋白颗粒的形态变化。结果组Ⅰ各时间点各项指标无明显变化。升主动脉阻断期间,组Ⅱ－ⅢａＫ－ＡＴＰａｓｅ活性均显著下降（ＡＣＣ１５ｍｉｎ ｕｓ ＡＣＣ６０ｍｉｎ,Ｐ〈０．０１）,组ⅡＣａＭｇ－ＡＴＰａｓｅ活性单位面积心肌细胞膜蛋白颗     

四物汤对红细胞免疫及骨髓干细胞增殖能力的影响

用四物汤对辐射损伤小鼠进行治疗.结果表明:电离辐射对小鼠红细胞免疫功能及骨髓干细胞增殖能力有明显的抑制作用,应用四物汤治疗后红细胞免疫功能得到恢复,说明四物汤有较明显的增强红细胞免疫功能的作用.由骨髓干细胞增殖实验中可看出四物汤可使受照小鼠的骨髓干细胞增殖能力恢复正常.该研究为四物汤治疗辐射损伤引起的红细胞免疫功能及造血功能低下提供了实验依据.     

基于体表生理信号的呼吸功能监测仪研制

目的：研制一款基于体表心电、膈肌电和胸阻抗信号的呼吸功能监测仪原理样机,可在家庭、医疗急救等场合实现对呼吸功能的持续监测。方法：以STM32F411VET6单片机开发系统为平台,用一对Ag/AgCl电极作为高频激励信号的输出和心电、胸阻抗信号的检测电极,另一对Ag/AgCl电极作为膈肌电信号检测电极,两对电极同时检测心电、膈肌电和胸阻抗信号。系统硬件主要包括心电信号检测电路、胸阻抗信号检测电路、膈肌电信号检测电路、恒流源激励电路以及微控制器。系统采用12 V可充电锂电池供电,模拟信号通过单片机A/D转换成数字信号,通过SDIO接口存储于SD卡。在完成样机制作和性能测试之后,采集13例因呼吸功能障碍实施机械通气患者和13例健康成年人的信号,计算15个与呼吸功能相关的参数,比较机械通气患者与健康对照组参数之间的差异,验证了呼吸功能监测仪的可靠性。结果：样机采集信号的信噪比>10 dB、共模抑制比>80 dB,样机漏电流<30μA。机械通气患者的吸气时间、呼气时间、潮气量、胸阻抗峰峰值、胸阻抗1 s变化量、膈肌电低频功率、膈肌电高频功率、高频比低频、膈肌放电面积、膈肌放电时...     

Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1

PurposeMost patients with Gaucher disease have progressive and often disabling skeletal manifestations. We examined the long-term effect of eliglustat treatment on bone outcomes in clinical trials in adults with Gaucher disease type 1.MethodsData from 4 completed phase 2 and 3 trials were evaluated in treatment-naïve patients or patients switching to eliglustat from enzyme replacement therapy (ERT).ResultsOverall, 319 of 393 (81%) eliglustat-treated patients remained in their trials until completion or commercial eliglustat became available. Mean eliglustat treatment duration ranged from 3.3 to 6.5 years. In treatment-naïve patients and ERT-switch patients, frequency and severity of bone pain decreased during eliglustat treatment. Mean lumbar spine T-scores shifted from abnormal to normal in treatment-naïve patients and remained in the healthy reference range or improved modestly in ERT-switch patients. Mean total bone marrow burden score shifted from marked-to-severe to moderate in treatment-naïve patients and remained moderate in ERT-switch patients. MIP-1β (marker of active bone disease) was elevated at baseline and decreased to the healthy reference range in treatment-naïve patients and remained in the healthy reference range among ERT-switch patients.ConclusionThese findings confirm the long-term efficacy of eliglustat on skeletal complications of Gaucher disease in treatment-naïve and ERT-switch patients.